08:00 , Feb 2, 2015 |  BC Week In Review  |  Company News

NewLink, GlaxoSmithKline, J&J, Merck, Pfizer, Sanofi, Global Alliance for Vaccine Immunization infectious news

GAVI said it raised $7.5 billion from countries and private donors that will be used along with $2 billion in existing funds to deliver vaccines to GAVI-supported countries in 2016-20. Of the $7.5 billion raised,...
02:28 , Jan 27, 2015 |  BC Extra  |  Company News

Pharmas pitch in on GAVI initiative

The Global Alliance for Vaccine Immunization (GAVI) announced commitments from private sector partners including Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ), Sanofi (Euronext:SAN; NYSE:SNY), Merck...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

Ixiaro regulatory update

The World Health Organization (WHO) awarded prequalification to Biological E's Japanese Encephalitis (JE) vaccine for worldwide use in adults. Biological E expects WHO to extend the prequalification to include pediatric use by year end. The...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Biological E., Novartis deal

Biological E received development and commercialization rights in the developing world to two Novartis vaccines - a vaccine against typhoid fever and a dual-acting vaccine against typhoid and paratyphoid fevers. The not-for-profit Novartis Vaccines Institute...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Ixiaro regulatory update

Valneva said the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for Ixiaro Japanese Encephalitis (JE) vaccine to include use in pediatric individuals ages >=2 months....
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Biological E., Valneva deal

Valneva sold its clinical manufacturing operations facility in Nantes, France, to Biological E for an undisclosed price. Valneva said the purchase is part of its strategy to realize cost synergies of €5-€6 million ($6.6-$7.9 million)...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

Ixiaro regulatory update

Intercell said FDA approved Ixiaro Japanese Encephalitis (JE) vaccine to include pediatric patients. The product is marketed for adults as Ixiaro in Canada, Europe, Hong Kong, Israel, Singapore and the U.S., where it has Orphan...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Ixiaro regulatory update

Intercell said the European Commission approved a regulatory application for Ixiaro Japanese Encephalitis (JE) vaccine to include pediatric patients. An application for the pediatric indication is under review in the U.S., where it has Orphan...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Biological E Ltd., GlaxoSmithKline deal

GlaxoSmithKline and vaccines company Biological E will form a 50/50 JV to develop a pediatric vaccine for polio and other infectious diseases for developing countries, including India. The vaccine - which will combine GSK's injectable...
01:28 , Jan 29, 2013 |  BC Extra  |  Company News

GSK, Biological E forming JV for pediatric vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Indian vaccines company Biological E Ltd. (Hyderabad, India) will form a 50/50 JV to develop a pediatric vaccine for polio and other infectious diseases for developing countries, including India. The...